Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with Chronic Obstructive Pulmonary Disease (COPD)
umeclidinium bromide
AC4115321
NCT01372410
Pulmonary Disease, Chronic Obstructive
Phase 2
 
June 2014

Powered by ideaPoint, Inc.